Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care

James Harding, CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds." James Harding, CEO, Transdiagen added "We are thrilled to be...

James Harding, CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds."

The collaboration will be initiated shortly. 

For more information, please contact:

Jennifer Doak
Global Communications Director Wound Care
Email: [email protected]
Phone: +1 678 206 6179

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/molnlycke/r/molnlycke--health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-,c4056056

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-care-302286130.html